DE69426571T2 - TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen - Google Patents

TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen

Info

Publication number
DE69426571T2
DE69426571T2 DE69426571T DE69426571T DE69426571T2 DE 69426571 T2 DE69426571 T2 DE 69426571T2 DE 69426571 T DE69426571 T DE 69426571T DE 69426571 T DE69426571 T DE 69426571T DE 69426571 T2 DE69426571 T2 DE 69426571T2
Authority
DE
Germany
Prior art keywords
transgenic animals
swedish mutation
app alleles
house app
house
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69426571T
Other languages
English (en)
Other versions
DE69426571D1 (de
Inventor
Lisa C Mcconlogue
Jun Zhoa
Sinha Sukanto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Eli Lilly and Co
Original Assignee
Elan Pharmaceuticals LLC
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26841313&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69426571(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/143,697 external-priority patent/US5604102A/en
Application filed by Elan Pharmaceuticals LLC, Eli Lilly and Co filed Critical Elan Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69426571D1 publication Critical patent/DE69426571D1/de
Publication of DE69426571T2 publication Critical patent/DE69426571T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Catching Or Destruction (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69426571T 1993-10-27 1994-10-18 TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen Expired - Lifetime DE69426571T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/143,697 US5604102A (en) 1992-04-15 1993-10-27 Methods of screening for β-amyloid peptide production inhibitors
US08/148,211 US5612486A (en) 1993-10-27 1993-11-01 Transgenic animals harboring APP allele having swedish mutation
PCT/US1994/011827 WO1995011968A1 (en) 1993-10-27 1994-10-18 Transgenic animals harboring app allele having swedish mutation

Publications (2)

Publication Number Publication Date
DE69426571D1 DE69426571D1 (de) 2001-02-15
DE69426571T2 true DE69426571T2 (de) 2001-08-09

Family

ID=26841313

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1001019T Pending DE1001019T1 (de) 1993-10-27 1994-10-18 Transgene Tiere, die APP Allele mit der schwedischen Mutation beherbergen
DE69426571T Expired - Lifetime DE69426571T2 (de) 1993-10-27 1994-10-18 TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1001019T Pending DE1001019T1 (de) 1993-10-27 1994-10-18 Transgene Tiere, die APP Allele mit der schwedischen Mutation beherbergen

Country Status (12)

Country Link
US (5) US5850003A (de)
EP (2) EP1001019A1 (de)
JP (3) JPH09507746A (de)
AT (1) ATE198622T1 (de)
AU (1) AU702293B2 (de)
CA (1) CA2174429C (de)
DE (2) DE1001019T1 (de)
DK (1) DK0730643T3 (de)
ES (1) ES2155099T3 (de)
GR (1) GR3035564T3 (de)
PT (1) PT730643E (de)
WO (1) WO1995011968A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5586226A (en) * 1990-05-16 1996-12-17 Canon Kabushiki Kaisha Control method and device for a unicolor printer
ES2204899T3 (es) * 1992-01-07 2004-05-01 Elan Pharmaceuticals, Inc. Modelos de animales transgenicos para la enfermedad de alzheimer.
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
ATE198622T1 (de) * 1993-10-27 2001-01-15 Elan Pharm Inc Transgene tiere, die app allele mit der schwedischen mutation beherbergen
WO1995020666A2 (en) 1994-01-27 1995-08-03 Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5777194A (en) * 1995-04-26 1998-07-07 Cephalon, Inc. Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
JPH11507821A (ja) * 1995-06-07 1999-07-13 アセナ ニューロサイエンシーズ，インコーポレイテッド トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
WO1996040895A1 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
US20010016951A1 (en) 1996-07-24 2001-08-23 Bernd Sommer Transgenic animal model for alzheimer disease
EP0920495B1 (de) * 1996-07-24 2008-05-07 Novartis AG Transgentier-modell für die krankheit von alzheimer
WO1999009150A1 (en) * 1996-08-15 1999-02-25 Bayer Corporation Method of introducing modifications into a gene
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
EP0948612A2 (de) * 1997-01-03 1999-10-13 University Technology Corporation Beta-amyloid toxizität
WO1998046726A1 (en) * 1997-04-15 1998-10-22 Temple University - Of The Commonwealth System Of Higher Education A-myb NULL MUTANT TRANSGENIC ANIMALS AND USES THEREOF
US6284944B1 (en) * 1997-08-29 2001-09-04 Cephalon, Inc, Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
CN1502692A (zh) * 1998-09-24 2004-06-09 �������Ŷ���Լ��������˾ 阿尔茨海默氏疾病分泌酶
US6844148B1 (en) * 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) * 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
US7115410B1 (en) * 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
EP1165609A2 (de) 1999-02-10 2002-01-02 Elan Pharmaceuticals, Inc. Menschliches beta-secretase enzym, inhibitoren und ihre zusammensetzungen und verwendungen
EP1063298A3 (de) * 1999-06-04 2001-03-28 Glaxo Group Limited Transgenes Tiermodell für die Krankheit von Alzheimer
AU5890400A (en) * 1999-06-24 2001-01-09 Baylor College Of Medicine System and method to detect compounds and mutations that upregulate and downregulate expression of nucleotide sequences
US20090162883A1 (en) * 1999-09-23 2009-06-25 Pharmacia & Upjohn Company Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
DE60144164D1 (de) 2000-06-20 2011-04-14 Univ Toronto Transgenes Tiermodel für neurodegenerative Krankheiten
US7371920B2 (en) * 2000-06-20 2008-05-13 The Governing Council Of The University Of Toronto Transgenic mouse model of neurodegenerative disorders
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
ES2248356T3 (es) 2000-06-30 2006-03-16 Elan Pharmaceuticals, Inc. Compuestos para tratar la enfermedad de alzheimer.
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
AU2002230693B2 (en) * 2000-12-13 2006-08-17 Immunex Corporation Method for generating immortal dendritic cell lines
EP1395551B1 (de) * 2001-06-01 2008-05-21 Elan Pharmaceuticals, Inc. Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
JP2004532894A (ja) 2001-06-13 2004-10-28 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療するためのアミンジオール
BR0210721A (pt) * 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
BR0211118A (pt) * 2001-07-10 2004-10-26 Elan Pharm Inc Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
US7053109B2 (en) * 2001-07-10 2006-05-30 Pharmacia & Upjohn Company Aminediols for the treatment of Alzheimer's disease
CA2462851A1 (en) 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
NZ533107A (en) * 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
KR100462180B1 (ko) * 2001-11-20 2004-12-16 (주) 디지탈바이오텍 알츠하이머병 병인 유전자로 형질전환된 동물 및 그 제조방법
US7479579B2 (en) * 2001-12-20 2009-01-20 The Regents Of The University Of California Triple transgenic mouse model of Alzheimer's disease
US20040016008A1 (en) * 2002-01-07 2004-01-22 Brimijoin William Stephen Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
JP2005518791A (ja) * 2002-02-27 2005-06-30 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Ｉｍｒ−３２細胞からのアミロイド−ベータペプチドの高レベル生産
AU2003303141A1 (en) * 2002-04-30 2004-07-22 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
JP2004000060A (ja) * 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
BR0316629A (pt) * 2002-11-27 2005-10-11 Elan Pharm Inc Uréias e carbamatos substituìdos
BRPI0409627A (pt) * 2003-04-21 2006-04-25 Elan Pharm Inc 2-hidróxi-3-diaminoalcanos de fenacila
AR044044A1 (es) 2003-04-21 2005-08-24 Elan Pharm Inc 2-hidroxi-3-diaminoalcanos de benzamida
EP1628666B1 (de) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Verbindungen und ihre verwendungen zur modulierung von amyloid beta
JP2007522129A (ja) * 2004-01-21 2007-08-09 エラン ファーマシューティカルズ，インコーポレイテッド アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法
EP1734942A1 (de) 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Substituierte harnstoff und carbamat, phenacyl-2-hydroxy-3-diaminoalkan, und benzamid-2-hydroxy-3-diaminoalkan aspartyl-proteasehemmer
EP1734961A2 (de) * 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Verfahren zur behandlung von amyloidose mit bicyclischen aspartyl-proteasehemmern
CA2558034A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
WO2005087752A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
KR100584914B1 (ko) * 2004-03-30 2006-05-30 주식회사 뉴로테크 돌연변이 ａｐｐ를 발현하는 알츠하이머병 유발 형질전환마우스
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
EP1750719A2 (de) * 2004-05-19 2007-02-14 Boehringer Ingelheim International GmbH Behandlung von erkrankungen im zusammenhang mit veränderten spiegeln von amyloid-betapeptiden
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CA2572775A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
CA2573138A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) * 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
EP1802574A2 (de) * 2004-08-27 2007-07-04 Elan Pharmaceuticals Inc. Verfahren zur behandlung von amyloidose mit ethanolcyclicaminderivat-aspartylproteasehemmern
AU2005304931A1 (en) * 2004-11-05 2006-05-18 Wyeth Pet and magnetic resonance for screening Alzheimer's disease therapeutics
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
US20060272038A1 (en) * 2005-05-27 2006-11-30 Michael De Vivo Transgenic Alzheimer's mouse model vectors and uses thereof
EP1746092A1 (de) 2005-07-22 2007-01-24 Exonhit Therapeutics SA Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
US20080293680A1 (en) * 2005-08-03 2008-11-27 Stefan Peters Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
US20090042867A1 (en) * 2005-08-11 2009-02-12 Klaus Fuchs Compounds for the treatment of alzheimer's disease
WO2007017507A1 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
JP2009511589A (ja) * 2005-10-12 2009-03-19 エラン ファーマシューティカルズ，インコーポレイテッド アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7932261B2 (en) * 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7868022B2 (en) * 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7776882B2 (en) * 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
JP5033868B2 (ja) * 2006-03-23 2012-09-26 バイオアークティック ニューロサイエンス アーベー 改良型プロトフィブリル選択的抗体及びその使用
TW200808751A (en) * 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
US20070292895A1 (en) * 2006-05-19 2007-12-20 Xiao-Ping Shi Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
TW200815349A (en) * 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
CA2666246C (en) 2006-10-12 2013-12-31 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
JP5450407B2 (ja) 2007-07-06 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法
WO2009012237A1 (en) 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
CA2713998A1 (en) * 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace)
WO2009097401A1 (en) * 2008-01-29 2009-08-06 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
AU2009313851A1 (en) * 2008-11-13 2010-05-20 Modgene, Llc Modification of amyloid-beta load in non-brain tissue
WO2010056195A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
TW201020244A (en) * 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
WO2010056194A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab 5h-pyrrolo [ 3, 4-b] pyridin derivatives and their use
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
BR112013003847A8 (pt) 2010-08-19 2017-12-26 Buck Institute For Age Res métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
JP6096205B2 (ja) 2011-11-01 2017-03-15 モッドジーン リミテッド ライアビリティ カンパニーＭｏｄｇｅｎｅ，Ｌｌｃ 低減されたタンパク質キナーゼ阻害を呈するイマチニブ誘導体の使用
PL2637487T3 (pl) 2012-03-05 2015-04-30 Stulz Gmbh Klimatyzator do chłodzenia urządzeń elektronicznych lub szaf na urządzenia elektroniczne z blachą do ulepszonego prowadzenia powietrza
ES2667861T3 (es) 2012-03-05 2018-05-14 Stulz Gmbh Aparato climatizador para la refrigeración de aparatos electrónicos o armarios de instrumentos electrónicos con rejilla de soplado
WO2013142370A1 (en) 2012-03-19 2013-09-26 Varghese John APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF
US10202355B2 (en) 2013-02-12 2019-02-12 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
WO2014145562A1 (en) * 2013-03-15 2014-09-18 Powervision, Inc. Intraocular lens storage and loading devices and methods of use
MA40224B1 (fr) 2014-07-10 2021-05-31 Eisai R&D Man Co Ltd Anticorps se liant aux protofibrilles ass améliorés
US20170335324A1 (en) 2014-11-12 2017-11-23 The General Hospital Corporation Methods for treating neurodegenerative diseases
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
AU2016311502B2 (en) 2015-08-27 2019-07-18 Nantneuro, Llc Compositions for app-selective bace inhibition and uses therfor
WO2017179646A1 (ja) * 2016-04-14 2017-10-19 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物
IL262957B2 (en) 2016-05-12 2024-04-01 Buck Inst Res Aging 6-Fluorotropistrone and a pharmaceutical formulation comprising it for the relief of amyloid-related diseases
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
WO2023246838A1 (en) * 2022-06-22 2023-12-28 Tsinghua University Disease model and use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
BR8401386A (pt) * 1983-03-30 1984-11-06 Du Pont Conector de filtro
US4492760A (en) 1983-04-19 1985-01-08 The Wistar Institute Of Anatomy And Biology HLA D Typing assay
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) * 1985-10-28 1987-05-09 Teijin Ltd 遺伝子断片およびプラスミド
JPS63501765A (ja) * 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4666682A (en) * 1985-11-25 1987-05-19 James L. Mayer Dispenser for solid and powered detergent
US5547841A (en) 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
US5134062A (en) * 1988-03-22 1992-07-28 Cornell Research Foundation, Inc. Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
WO1990012870A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
AU5439790A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5221607A (en) 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
AU7121191A (en) 1990-02-26 1991-10-10 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for alzheimer's disease
EP0527823A1 (de) * 1990-04-24 1993-02-24 The Regents Of The University Of California Reinigung, nachweis und verfahren zur verwendung der protease-nexin-2
ES2217250T3 (es) * 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
WO1992000521A1 (en) * 1990-06-29 1992-01-09 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) * 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) * 1990-11-27 1992-02-25 Will L F & Cie Sa Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
ES2236682T5 (es) * 1991-01-21 2011-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
GB9116030D0 (en) 1991-07-25 1991-09-11 Ssali Charles L Antiviral compositions
ES2204899T3 (es) 1992-01-07 2004-05-01 Elan Pharmaceuticals, Inc. Modelos de animales transgenicos para la enfermedad de alzheimer.
SE511886C2 (sv) * 1992-01-31 1999-12-13 Svedala Arbra Ab Sätt att styra en gyratorisk kross
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5455169A (en) * 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
NZ253943A (en) 1992-06-18 1997-01-29 Genpharm Int Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994001772A1 (en) 1992-07-13 1994-01-20 The Children's Medical Center Corporation SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
ES2203620T3 (es) 1992-10-26 2004-04-16 Elan Pharmaceuticals, Inc. Procedimientos para la identificacion de los inhibidores de la produccion del peptido beta-amiloide.
EP0683234B2 (de) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
WO1994023049A2 (en) * 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
ATE198622T1 (de) * 1993-10-27 2001-01-15 Elan Pharm Inc Transgene tiere, die app allele mit der schwedischen mutation beherbergen

Also Published As

Publication number Publication date
JP2006122059A (ja) 2006-05-18
DE1001019T1 (de) 2001-01-11
CA2174429A1 (en) 1995-05-04
GR3035564T3 (en) 2001-06-29
PT730643E (pt) 2001-06-29
US20020049988A1 (en) 2002-04-25
US20070199079A1 (en) 2007-08-23
EP0730643A1 (de) 1996-09-11
AU8080994A (en) 1995-05-22
JP2007267748A (ja) 2007-10-18
CA2174429C (en) 2011-08-30
EP0730643B1 (de) 2001-01-10
AU702293B2 (en) 1999-02-18
DE69426571D1 (de) 2001-02-15
EP1001019A1 (de) 2000-05-17
EP0730643A4 (de) 1996-11-27
ATE198622T1 (de) 2001-01-15
US5850003A (en) 1998-12-15
ES2155099T3 (es) 2001-05-01
DK0730643T3 (da) 2001-05-14
JPH09507746A (ja) 1997-08-12
US7608749B2 (en) 2009-10-27
US6245964B1 (en) 2001-06-12
WO1995011968A1 (en) 1995-05-04
US6586656B2 (en) 2003-07-01
US7179953B2 (en) 2007-02-20
US20050022257A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
DE69426571D1 (de) TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen
ATE278023T1 (de) Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
DK0748386T3 (da) Frembringelse af fibrinogen i transgene dyr
FR2700441B1 (fr) Perchoir pour animaux de compagnie.
DE69929324D1 (de) TRANSGENE Mäuse MIT VERÄNDERTER APOLIPOPROTEIN E-EXPRESSION UND TESTVERFAHREN.
DE3883327T2 (de) Strahlformungsnetzwerk mit mehreren stufen.
PT692869E (pt) Amplificador de potencia com controlo de nivel de limitador
ATE288923T1 (de) Cd4-gamma2- und cd4-igg2-chimären
DE69109141T2 (de) Laserdiode mit stabilisiertem Transversal-Mode.
FR2743979B1 (fr) Robot taille-haies telecommande avec reglage automatique des niveaux
DE69425314T2 (de) Gebäude zur Unterbringung von Tieren
DE3587117T2 (de) Optischer sender mit antriebsschaltung.
ATE308611T1 (de) Phage verbunden an ein nukleus lokalisierungssignal
DK0638231T3 (da) Konstruktion til automatisk malkning af dyr
CA2311599A1 (en) Transgenic non-human mammals with an oncogenic mutant of raf gene 1
ES2108061T3 (es) Gen quimerico que comprende un promotor-regulador y un gen que codifica una proteina indicadora.
ES1030520Y (es) Silo regulador de alimentacion de ganado.
FR2716754B1 (fr) Limiteur de courant avec module de calibrage.
WO1992004443A3 (en) B cell deficient transgenic fbv/n mice
DE69104741T2 (de) Kopiergerät mit Bildeditor.
IT1297272B1 (it) Sistema di telecomando con programmazione di codice
DE9311945U1 (de) Pferdeführleine
IT7822470A0 (it) Centrale di programmazione e comando per stazione radio-video trasmittente o simile.
DK126393D0 (da) Foderadditiv til husdyr
IT8460409V0 (it) Remo con pala di tela e luce di servizio elettrica.

Legal Events

Date Code Title Description
8363 Opposition against the patent